SYH9017

SYH9017 is a long-acting, once-monthly formulation of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. for weight management in overweight or obese adults. As a biologic therapeutic, it targets the GLP-1 receptor to regulate appetite and caloric intake. Unlike existing weekly semaglutide formulations such as Wegovy, SYH9017 is designed to extend the dosing interval to once per month, which may significantly improve patient adherence. In December 2024, the drug received approval from China's National Medical Products Administration (NMPA) to begin Phase I clinical trials. These studies, including single ascending dose (SAD) and multiple ascending dose (MAD) protocols, are evaluating the safety, tolerability, pharmacokinetics, and weight-loss efficacy of the drug in Chinese adults.

Other names

long-acting semaglutide injection